FDA Approves CEFEPIME HYDROCHLORIDE AND DEXTROSE — B. Braun Medical Inc.
B. Braun Medical Inc. earned FDA approval today for Cefepime Hydrochloride and Dextrose Intravenous injection, a strategic addition to its hospital portfolio that positions the company to capitalize on growing demand for critical care antibiotic treatments.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day